European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke.
Joanna Marguerite WardlawHugues ChabriatFrank-Erik de LeeuwStephanie DebetteMartin DichgansFergus N DoubalHanna JokinenAristeidis H KatsanosRaffaele OrnelloLeonardo PantoniMarco PasiAleksandra M PavlovićSalvatore RudilossoReinhold SchmidtJulie StaalsMartin Taylor-RowanSalman HussainArne G LindgrenPublished in: European stroke journal (2024)
A quarter of ischaemic strokes are lacunar subtype, typically neurologically mild, usually resulting from intrinsic cerebral small vessel pathology, with risk factor profiles and outcome rates differing from other stroke subtypes. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations to assist with clinical decisions about management of lacunar ischaemic stroke to prevent adverse clinical outcomes. The guideline was developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We addressed acute treatment (including progressive lacunar stroke) and secondary prevention in lacunar ischaemic stroke, and prioritised the interventions of thrombolysis, antiplatelet drugs, blood pressure lowering, lipid lowering, lifestyle, and other interventions and their potential effects on the clinical outcomes recurrent stroke, dependency, major adverse cardiovascular events, death, cognitive decline, mobility, gait, or mood disorders. We systematically reviewed the literature, assessed the evidence and where feasible formulated evidence-based recommendations, and expert concensus statements. We found little direct evidence, mostly of low quality. We recommend that patients with suspected acute lacunar ischaemic stroke receive intravenous alteplase, antiplatelet drugs and avoid blood pressure lowering according to current acute ischaemic stroke guidelines. For secondary prevention, we recommend single antiplatelet treatment long-term, blood pressure control, and lipid lowering according to current guidelines. We recommend smoking cessation, regular exercise, other healthy lifestyle modifications, and avoid obesity for general health benefits. We cannot make any recommendation concerning progressive stroke or other drugs. Large randomised controlled trials with clinically important endpoints, including cognitive endpoints, are a priority for lacunar ischaemic stroke.
Keyphrases
- blood pressure
- atrial fibrillation
- cardiovascular events
- cognitive decline
- clinical practice
- smoking cessation
- physical activity
- liver failure
- metabolic syndrome
- weight loss
- drug induced
- cardiovascular disease
- pulmonary embolism
- respiratory failure
- systematic review
- healthcare
- coronary artery disease
- public health
- insulin resistance
- multiple sclerosis
- type diabetes
- hypertensive patients
- mild cognitive impairment
- replacement therapy
- bipolar disorder
- heart rate
- low dose
- intensive care unit
- fatty acid
- high dose
- risk assessment
- depressive symptoms
- high fat diet induced
- high intensity
- climate change
- quality improvement